MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 1900
- Registration Number
- NCT02508194
- Locations
- 🇿🇦
Research Site, Somerset West, South Africa
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 192
- Registration Number
- NCT02503774
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 301
- Registration Number
- NCT02473510
- Locations
- 🇺🇸
Research Site, Portland, Oregon, United States
A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 362
- Registration Number
- NCT02394314
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study to Assess the Safety of MEDI7836 in Healthy Adults.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 79
- Registration Number
- NCT02388347
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 94
- Registration Number
- NCT02350751
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 204
- Registration Number
- NCT02347176
- Locations
- 🇵🇱
Research Site, Łódź, Poland
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 114
- Registration Number
- NCT02340975
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 32
- Registration Number
- NCT02334306
- Locations
- 🇬🇧
Research Site, Swindon, United Kingdom
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 56
- Registration Number
- NCT02318394
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath